CD Formulation recently announces the enrichment of its active pharmaceutical ingredient excipient offerings.
Online PR News – 06-May-2022 – NY – Continuing to be a trust-worthy CRO company for drug formulation and development, CD Formulation recently announces the enrichment of its active pharmaceutical ingredient excipient offerings. Now a number of API excipients are readily obtainable at CD Formulation, including Cetrorelix Acetate, Fondaparinux Sodium, Calcitriol, Vitamine D3, Tirofiban Hydrochloride, Eptifibatide, Ferric Ammonium Citrate, Calcipotriol API, Calcium Orotate, Meglumine, Obeticholic Acid, Potassium Magnesium Citrate and Magnesium Oxide.
Both active pharmaceutical ingredients (APIs) and excipients are the two core components by which drugs are made up. APIs refer to the biologically active ingredients of pharmaceutical products, while excipients are chemically inactive substances that help deliver the medication to people’s systems.
“The main purpose of excipients is to enhance the effect of the active ingredients in the medicine, in each possible aspect. For instance, binder excipients act as a binder to bind powder, granules, and other dry ingredients together to give the product the necessary mechanical strength. Penetration enhancer excipients help to absorb the API through the skin into the body. Stiffening agents are used primarily in topical preparations to increase the viscosity of the preparation,” says a senior scientist from CD Formulation.
Among all the newly launched API excipients, cetrorelix acetate is a white powder that can be used as a component of controlled ovarian stimulation regimens. Fondaparinux sodium can be used in anti-thrombotic applications. Eptifibatide can serve as a platelet aggregation inhibitor. The ferric ammonium citrate provided is of pharmaceutical secondary standard and tirofiban hydrochloride is of medical grade. Magnesium oxide possesses a cubic crystalline structure, although the BP and PhEur describe light magnesium oxide as an amorphous powder. Meglumine is an excipient used in Telmesartan tablets.
In addition to those already readily available API excipients, CD Formulation also offers tailored synthesis and manufacturing services for clients worldwide who have special requirements on the type, quality, and quantity of excipients. With concerted efforts from both sides, CD Formulation aims to bring out the best-performing excipients and ultimately make the contracted drug research project a success. Please visit https://www.formulationbio.com/custom-pharmaceutical-excipients.html to explore more.
About CD Formulation
As a service provider for excipient development, analysis and testing as well as drug formulation, CD Formulation feels a great honor to have successfully accomplished several drug formulation research projects for its customers. Encouraged by the persistent trust from its partners, the company decides to further enrich its business range to provide a more comprehensive service portfolio for its valued customers worldwide. Among these, drug packaging services are newly added to help developers establish a unique and easy-to-distinguish drug packaging.